Lee J H, Miele M E, Hicks D J, Phillips K K, Trent J M, Weissman B E, Welch D R
Department of Experimental Pathology, Jake Gittlen Cancer Research Institute, College of Medicine, Pennsylvania State University, Hershey 17033-0850, USA.
J Natl Cancer Inst. 1996 Dec 4;88(23):1731-7. doi: 10.1093/jnci/88.23.1731.
Microcell-mediated transfer of chromosome 6 into human C8161 and MelJuSo melanoma cell suppresses their ability to metastasize by at least 95% without affecting their tumorigenicity. This observation demonstrates that the ability to metastasize is a phenotype distinct from tumor formation and suggests that tumorigenic cells acquire metastatic capability only after accumulating additional genetic defects. These results also imply that mutations of genes on chromosome 6 are among those late genetic changes responsible for metastatic potential. They further suggest that a melanoma metastasis-suppressor gene(s) is encoded on chromosome 6 or is regulated by genes on chromosome 6.
Our objective was to identify the gene(s) responsible for the suppression of metastasis in chromosome 6/melanoma cell hybrids.
A modified subtractive hybridization technique was used to compare the expression of messenger RNAs (mRNAs), via an analysis of complementary DNAs (cDNAs), in metastatic cells (C8161 or MelJuSo) and nonmetastatic hybrid clones (neo6/C8161 or neo6/MelJuSo).
A novel cDNA, designated KiSS-1, was isolated from malignant melanoma cells that had been suppressed for metastatic potential by the introduction of human chromosome 6. Northern blot analyses comparing mRNAs from a panel of human melanoma cells revealed that KiSS-1 mRNA expression occurred only in nonmetastatic melanoma cells. Expression of this mRNA in normal heart, brain, liver, lung, and skeletal muscle was undetectable by northern blot analysis. Weak expression was found in the kidney and pancreas, but the highest expression was observed in the placenta. The KiSS-1 cDNA encodes a predominantly hydrophilic, 164 amino acid protein with a polyproline-rich domain indicative of an SH3 ligand (binds to the homology 3 domain of the oncoprotein Src) and a putative protein kinase C-alpha phosphorylation site. Transfection of a full-length KiSS-1 cDNA into C8161 melanoma cells suppressed metastasis in an expression-dependent manner.
These data strongly suggest that KiSS-1 expression may suppress the metastatic potential of malignant melanoma cells.
KiSS-1 may be a useful marker for distinguishing metastatic melanomas from nonmetastatic melanomas.
通过微细胞介导将6号染色体导入人C8161和MelJuSo黑色素瘤细胞,可使其转移能力至少降低95%,且不影响其致瘤性。这一观察结果表明,转移能力是一种有别于肿瘤形成的表型,提示致瘤细胞只有在积累了额外的基因缺陷后才获得转移能力。这些结果还意味着,6号染色体上的基因突变是导致转移潜能的晚期基因变化之一。它们进一步表明,黑色素瘤转移抑制基因位于6号染色体上,或受6号染色体上的基因调控。
我们的目标是鉴定6号染色体/黑色素瘤细胞杂交体中负责抑制转移的基因。
采用改良的消减杂交技术,通过分析互补DNA(cDNA)来比较转移性细胞(C8161或MelJuSo)和非转移性杂交克隆(neo6/C8161或neo6/MelJuSo)中信使RNA(mRNA)的表达。
从通过导入人6号染色体而被抑制了转移潜能的恶性黑色素瘤细胞中分离出一种新的cDNA,命名为KiSS-1。对一组人黑色素瘤细胞的mRNA进行Northern印迹分析比较发现,KiSS-1 mRNA仅在非转移性黑色素瘤细胞中表达。通过Northern印迹分析在正常心脏、大脑、肝脏、肺和骨骼肌中未检测到该mRNA的表达。在肾脏和胰腺中发现有微弱表达,但在胎盘中表达最高。KiSS-1 cDNA编码一种主要为亲水性的164个氨基酸的蛋白质,具有富含多聚脯氨酸的结构域,提示其为SH3配体(与癌蛋白Src的同源3结构域结合)以及一个假定的蛋白激酶C-α磷酸化位点。将全长KiSS-1 cDNA转染到C8161黑色素瘤细胞中,以表达依赖的方式抑制了转移。
这些数据强烈提示KiSS-1的表达可能抑制恶性黑色素瘤细胞的转移潜能。
KiSS-1可能是区分转移性黑色素瘤和非转移性黑色素瘤的有用标志物。